Ozempic (semaglutide) slows gastric emptying significantly in the early weeks of treatment, roughly doubling the time it takes your stomach to process a solid meal. In one study of women on semaglutide 1.0 mg for eight weeks, the half-emptying time for a solid meal was 171 minutes compared to 118 minutes on placebo. That’s nearly an extra hour before your stomach moves half its contents into the small intestine. But the effect appears to fade with continued use, and by 20 weeks it may no longer be measurable at all.
What Happens in Your Stomach
When you eat, your gut naturally releases a hormone called GLP-1 that activates receptors in several places: the pancreas (triggering insulin), the brain’s appetite centers (promoting fullness), and the nerve cells in your stomach wall (slowing digestion). Ozempic mimics this hormone but at much higher, longer-lasting levels than your body produces on its own. The result is that food sits in your stomach longer before being pushed into the small intestine, which contributes to the prolonged feeling of fullness many users describe.
How Long the Delay Actually Lasts
The most precise data comes from a study using scintigraphic imaging, which tracks a radioactive tracer in food as it moves through the digestive system. After eight weeks on semaglutide 1.0 mg, participants retained 37% of a solid meal in their stomachs at the four-hour mark. Participants on placebo retained 0% at that same point, meaning their stomachs had fully emptied. At just 30 minutes after eating, the difference was already apparent: 92.5% of the meal remained in the semaglutide group versus 89% in the placebo group.
The half-emptying time tells the clearest story. On placebo, it took about 118 minutes (just under two hours) for the stomach to move half the meal along. On semaglutide, that stretched to 171 minutes (nearly three hours). So per meal, you’re looking at roughly 50 extra minutes of food sitting in your stomach during active treatment at the 1.0 mg dose.
The Effect Fades Over Time
Here’s what surprises many people: the gastric emptying delay doesn’t appear to be permanent, even while you keep taking the medication. A study of semaglutide 2.4 mg (the higher dose used for weight management) found no measurable delay in gastric emptying at week 20, despite clear effects on appetite and food intake. Researchers measured this using paracetamol absorption, a standard indirect test for how quickly your stomach empties liquids.
This fading effect is called tachyphylaxis, where the body gradually adapts to a drug’s influence on a specific function. A 12-week study at the 1.0 mg dose did show a delay in first-hour gastric emptying, suggesting the effect is still present at three months but may weaken somewhere between weeks 12 and 20. The practical takeaway: the heavy, “food sitting like a brick” sensation that many new users report tends to ease as treatment continues, and this isn’t just your imagination. Your stomach is genuinely adapting.
Importantly, semaglutide’s appetite-suppressing and weight loss effects persist well beyond this window. The drug works on brain appetite centers independently of stomach motility, so losing the gastric emptying effect doesn’t mean the medication stops working.
Why This Matters for Side Effects
The delayed emptying is directly linked to the nausea, bloating, and vomiting that many Ozempic users experience, especially in the first weeks. Food lingering in the stomach longer than usual triggers discomfort, and for some people it can be severe enough to resemble gastroparesis, a condition where the stomach empties abnormally slowly on a chronic basis.
Research using a database of roughly 88 million patients found that people with type 2 diabetes who used GLP-1 receptor agonists (the drug class that includes semaglutide) had a significantly increased risk of being diagnosed with gastroparesis. That elevated risk appeared as early as six months after starting treatment and persisted through at least 24 months. This doesn’t mean everyone on Ozempic develops gastroparesis, but it suggests the stomach-slowing effect can become clinically significant in some people rather than resolving with adaptation.
Implications for Surgery and Anesthesia
Because food may remain in your stomach longer than expected, anesthesiologists have raised concerns about aspiration risk during surgery. Updated multi-society guidance from the American Society of Anesthesiologists offers a more nuanced approach than simply stopping the drug weeks in advance.
Most patients can continue their GLP-1 medication before elective surgery. However, if you’re still in the dose escalation phase (typically the first four to eight weeks, when side effects peak and gastric emptying is most affected), elective procedures should wait until that phase passes and any GI symptoms resolve. If you’re on a higher dose or experiencing active symptoms like nausea, vomiting, or abdominal pain, a 24-hour liquid diet before surgery is recommended. The key factor isn’t the drug itself but whether your stomach is actually emptying normally at the time of the procedure.
Effects on Other Medications You Take
Slower stomach emptying can change how quickly other pills you swallow reach your bloodstream. FDA pharmacokinetic data shows that semaglutide doesn’t cause clinically dangerous interactions with most common medications, but some drugs are affected more than others.
- Levothyroxine (thyroid medication): Total absorption increased by 33%, though peak blood levels were slightly lower. If you take thyroid medication, your doctor may need to recheck your levels after starting Ozempic.
- Furosemide (a diuretic): Peak blood levels dropped by 34%, meaning the drug hits your system more slowly and with less initial punch, even though total absorption increased by 28%.
- Rosuvastatin (a statin): Total absorption increased by 41%, which could amplify both the drug’s cholesterol-lowering effect and its side effects.
- Metformin: Total absorption increased by 32%, with no change in peak levels.
- Birth control pills, warfarin, lisinopril, digoxin: Minimal changes, generally not enough to require dose adjustments.
The pattern across these drugs is consistent: semaglutide tends to increase total drug absorption (because the medication spends more time in the stomach dissolving) while slightly reducing or not changing the peak concentration. For most medications this isn’t clinically meaningful, but for drugs with narrow therapeutic windows like levothyroxine or warfarin, even modest shifts can matter over time.